Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans

[1]  D. Uppala,et al.  Oncogenesis , 2018, Concise Notes in Oncology for MRCP and MRCS.

[2]  D. Calvisi,et al.  Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice , 2018, Oncogene.

[3]  E. Oki,et al.  High expression of the Notch ligand Jagged‐1 is associated with poor prognosis after surgery for colorectal cancer , 2016, Cancer science.

[4]  Shi-qiang Shen,et al.  A study of the role of Notch1 and JAG1 gene methylation in development of breast cancer , 2016, Medical Oncology.

[5]  D. Calvisi,et al.  Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice , 2016, Scientific Reports.

[6]  V. Baladrón,et al.  The complex role of NOTCH receptors and their ligands in the development of hepatoblastoma, cholangiocarcinoma and hepatocellular carcinoma , 2016, Biology of the cell.

[7]  Shiying Yu,et al.  Notch signaling: an emerging therapeutic target for cancer treatment. , 2015, Cancer letters.

[8]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[9]  N. Hadi,et al.  Notch1 ligand signaling pathway activated in cervical cancer: poor prognosis with high-level JAG1/Notch1 , 2015, Archives of Gynecology and Obstetrics.

[10]  U. Neumann,et al.  Role of surgery in cholangiocarcinoma: From resection to transplantation. , 2015, Best practice & research. Clinical gastroenterology.

[11]  A. Vogel,et al.  Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies. , 2015, Best practice & research. Clinical gastroenterology.

[12]  A. Zhu.  Future directions in the treatment of cholangiocarcinoma. , 2015, Best practice & research. Clinical gastroenterology.

[13]  Grégoire Pau,et al.  Differential effects of targeting Notch receptors in a mouse model of liver cancer , 2015, Hepatology.

[14]  M. Strazzabosco,et al.  Emerging roles of Notch signaling in liver disease , 2015, Hepatology.

[15]  A. Harris,et al.  The Notch Ligand Jagged1 as a Target for Anti-Tumor Therapy , 2014, Front. Oncol..

[16]  Prakash Kulkarni,et al.  Correlation of Sprouty1 and Jagged1 With Aggressive Prostate Cancer Cells With Different Sensitivities to Androgen Deprivation , 2014, Journal of cellular biochemistry.

[17]  D. Calvisi,et al.  Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. , 2014, Gastroenterology.

[18]  G. Gores,et al.  Molecular Pathogenesis of Cholangiocarcinoma , 2014, Digestive Diseases.

[19]  Lei-bo Xu,et al.  Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro. , 2014, Oncology reports.

[20]  G. Gores,et al.  Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting , 2014, Hepatology.

[21]  Yoshinori Murakami,et al.  Genomic and transcriptional alterations of cholangiocarcinoma , 2014, Journal of hepato-biliary-pancreatic sciences.

[22]  Lei-bo Xu,et al.  Clinicopathological significance of aberrant Notch receptors in intrahepatic cholangiocarcinoma. , 2014, International journal of clinical and experimental pathology.

[23]  D. Calvisi,et al.  Hydrodynamic transfection for generation of novel mouse models for liver cancer research. , 2014, The American journal of pathology.

[24]  Swe Swe Myint,et al.  Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.

[25]  T. Pawlik,et al.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.

[26]  D. Calvisi,et al.  On the role of notch1 and adult hepatocytes in murine intrahepatic cholangiocarcinoma development , 2013, Hepatology.

[27]  R. Plentz,et al.  Activation of Notch Signaling Is Required for Cholangiocarcinoma Progression and Is Enhanced by Inactivation of p53 In Vivo , 2013, PloS one.

[28]  R. Fiorotto,et al.  Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis. , 2013, Clinics and research in hepatology and gastroenterology.

[29]  Frank Bergmann,et al.  Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. , 2013, Gastroenterology.

[30]  D. Semela,et al.  Constitutive Notch2 signaling induces hepatic tumors in mice , 2013, Hepatology.

[31]  Sayaka Sekiya,et al.  Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. , 2012, The Journal of clinical investigation.

[32]  B. Stanger,et al.  Molecular mechanisms of liver and bile duct development , 2012, Wiley interdisciplinary reviews. Developmental biology.

[33]  G. Gores,et al.  Cholangiocarcinomas can originate from hepatocytes in mice. , 2012, The Journal of clinical investigation.

[34]  N. Spinner,et al.  Notch signaling in human development and disease. , 2012, Seminars in cell & developmental biology.

[35]  Itzhak Avital,et al.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.

[36]  D. Calvisi,et al.  AKT (v‐akt murine thymoma viral oncogene homolog 1) and N‐Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c‐Myc pathways , 2012, Hepatology.

[37]  G. Kristiansen,et al.  Expression and Clinicopathological Significance of Notch Signaling and Cell-Fate Genes in Biliary Tract Cancer , 2012, The American Journal of Gastroenterology.

[38]  S. Ellard,et al.  Alagille syndrome: pathogenesis, diagnosis and management , 2011, European Journal of Human Genetics.

[39]  H. El‐Serag,et al.  Risk factors for cholangiocarcinoma , 2011, Hepatology.

[40]  A. Capobianco,et al.  Notch signalling in solid tumours: a little bit of everything but not all the time , 2011, Nature Reviews Cancer.

[41]  T. Patel,et al.  Cholangiocarcinoma—controversies and challenges , 2011, Nature Reviews Gastroenterology &Hepatology.

[42]  D. Calvisi,et al.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. , 2011, Gastroenterology.

[43]  A. Antoniou,et al.  Biliary differentiation and bile duct morphogenesis in development and disease. , 2011, The international journal of biochemistry & cell biology.

[44]  G. Lockwood,et al.  High-level JAG1 mRNA and protein predict poor outcome in breast cancer , 2007, Modern Pathology.

[45]  Corey M. Carlson,et al.  Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[47]  S. Minoguchi,et al.  Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives. , 1997, Development.

[48]  M. Manns,et al.  A critical role for notch signaling in the formation of cholangiocellular carcinomas. , 2013, Cancer cell.

[49]  Yamanashi Prefectural.  Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells , 2013 .

[50]  A. Sirica.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma , 2012, Nature Reviews Gastroenterology &Hepatology.

[51]  G. Weinmaster,et al.  Canonical and non-canonical Notch ligands. , 2010, Current topics in developmental biology.

[52]  A. Wagers,et al.  Notch signaling in the regulation of stem cell self-renewal and differentiation. , 2010, Current topics in developmental biology.

[53]  V. Turusov,et al.  Tumours of the liver. , 1979, IARC scientific publications.

[54]  B. Jeppsson,et al.  Tumours in the liver. , 1978, Tijdschrift voor gastro-enterologie.